BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 16533976)

  • 1. Later-onset Fabry disease: an adult variant presenting with the cramp-fasciculation syndrome.
    Nance CS; Klein CJ; Banikazemi M; Dikman SH; Phelps RG; McArthur JC; Rodriguez M; Desnick RJ
    Arch Neurol; 2006 Mar; 63(3):453-7. PubMed ID: 16533976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical spectrum of Anderson Fabry disease in a Romanian family.
    Tudor A; Muşat A; Doscan A; Bari M; Zapucioiu C; Urdea E; Cochior D; Peţa D
    Rom J Intern Med; 2006; 44(2):201-10. PubMed ID: 17236300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fabry disease: molecular genetics of the inherited nephropathy.
    Desnick RJ; Astrin KH; Bishop DF
    Adv Nephrol Necker Hosp; 1989; 18():113-27. PubMed ID: 2564247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A missense mutation, A156T, in the alpha-galactosidase A gene causes typical Fabry disease.
    Konoshita T; Mutoh H; Yokoi T; Koni I; Miyamori I; Mabuchi H
    Clin Nephrol; 2001 Mar; 55(3):243-7. PubMed ID: 11316246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remarkable variability in renal disease in a large Slovenian family with Fabry disease.
    Verovnik F; Benko D; Vujkovac B; Linthorst GE
    Eur J Hum Genet; 2004 Aug; 12(8):678-81. PubMed ID: 15162124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma.
    Froissart R; Guffon N; Vanier MT; Desnick RJ; Maire I
    Mol Genet Metab; 2003 Nov; 80(3):307-14. PubMed ID: 14680977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of patients with Fabry disease in Argentina].
    AADELFA (Asociación Argentina de estudio de enfermedad de Fabry y otras enfermedades lisosomales)
    Medicina (B Aires); 2010; 70(1):37-43. PubMed ID: 20228022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fabry disease.
    Tarabuso AL
    Skinmed; 2011; 9(3):173-7. PubMed ID: 21675497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fabry disease: cardiac manifestations and therapeutic options.
    Pierre-Louis B; Kumar A; Frishman WH
    Cardiol Rev; 2009; 17(1):31-5. PubMed ID: 19092368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of cornea verticillata in hemizygotes of a novel mutation in fabry disease.
    Huerva V; Martín M; Canto LM; Yagüe J
    Cornea; 2008 Sep; 27(8):970-2. PubMed ID: 18724168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular genetics of inherited metabolic diseases--its application to the investigation of pathogenesis and the diagnosis of Fabry disease].
    Sakuraba H
    Rinsho Byori; 1994 Jun; 42(6):628-35. PubMed ID: 7914243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [alpha-Galactosidase gene mutation and its expression product in Fabry disease (alpha-galactosidase deficiency)].
    Okumiya T; Takata T; Sasaki M; Sakuraba H
    Rinsho Byori; 1997 Feb; 45(2):127-35. PubMed ID: 9120996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of multiple angiomas without any angiokeratomas in a female heterozygote with Fabry disease.
    Mirceva V; Hein R; Ring J; Möhrenschlager M
    Australas J Dermatol; 2010 Feb; 51(1):36-8. PubMed ID: 20148840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anderson-Fabry disease: a multiorgan disease.
    Tuttolomondo A; Pecoraro R; Simonetta I; Miceli S; Pinto A; Licata G
    Curr Pharm Des; 2013; 19(33):5974-96. PubMed ID: 23448451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Anderson-Fabry disease].
    Kes P; Basić-Jukić N; Brunetta B; Jurić I
    Acta Med Croatica; 2006; 60(1):55-8. PubMed ID: 16802573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypical characterization of α-galactosidase A gene mutations identified in a large Fabry disease screening program in stroke in the young.
    De Brabander I; Yperzeele L; Ceuterick-De Groote C; Brouns R; Baker R; Belachew S; Delbecq J; De Keulenaer G; Dethy S; Eyskens F; Fumal A; Hemelsoet D; Hughes D; Jeangette S; Nuytten D; Redondo P; Sadzot B; Sindic C; Sheorajpanday R; Thijs V; Van Broeckhoven C; De Deyn PP
    Clin Neurol Neurosurg; 2013 Jul; 115(7):1088-93. PubMed ID: 23219219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.
    Desnick RJ; Banikazemi M
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S172-85. PubMed ID: 17373219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel alpha-galactosidase a mutant (M42L) identified in a renal variant of Fabry disease.
    Rosenthal D; Lien YH; Lager D; Lai LW; Shang S; Leung N; Fervenza FC
    Am J Kidney Dis; 2004 Nov; 44(5):e85-9. PubMed ID: 15492942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fabry disease: clinic and enzymatic diagnosis of homozygous and heterozygous. New therapeutic prospects].
    Peces R; Olea T
    Nefrologia; 2002; 22(6):540-6. PubMed ID: 12516287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fabry disease: an ultrastructural comparative study of skin in hemizygous and heterozygous patients.
    Navarro C; Teijeira S; Dominguez C; Fernandez JM; Rivas E; Fachal C; Barrera S; Rodriguez C; Iranzo P
    Acta Neuropathol; 2006 Feb; 111(2):178-85. PubMed ID: 16463201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.